Get access
Advertisement

Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol

Authors

  • N. MYGIND,

    Corresponding author
    1. Otopathological Laboratory, University Department of Otorhinolaryngology, Rigshospitalet and University Department of Otorhinolaryngology, Copenhagen City Hospital, Copenhagen, Denmark
      Niels Mygind, Otopathological Laboratory, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
    Search for more papers by this author
  • C. BRAKE PEDERSEN,

    1. Otopathological Laboratory, University Department of Otorhinolaryngology, Rigshospitalet and University Department of Otorhinolaryngology, Copenhagen City Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • S. PRYTZ,

    1. Otopathological Laboratory, University Department of Otorhinolaryngology, Rigshospitalet and University Department of Otorhinolaryngology, Copenhagen City Hospital, Copenhagen, Denmark
    Search for more papers by this author
  • H. SØRENSEN

    1. Otopathological Laboratory, University Department of Otorhinolaryngology, Rigshospitalet and University Department of Otorhinolaryngology, Copenhagen City Hospital, Copenhagen, Denmark
    Search for more papers by this author

Niels Mygind, Otopathological Laboratory, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Summary

In a double-blind trial thirty-five patients with moderately-severe nasal polyposis were treated with intranasal beclomethasone dipropionate aerosol for 3 weeks. The dose given (400 γg/day) had only local effect on the symptoms. Judged by diary card scores the nasal symptoms were reduced to 52% of the pre-trial level for the whole group. Corrected for the placebo effect the percentage was 68. The reduction of symptoms was equally apportioned to the three symptoms, sneezing, nasal secretion and blockage.

The treatment was tolerated well, and it is concluded that intranasal treatment with beclomethasone dipropionate aerosol offers most patients with nasal polyps a good response without any risk of systemic steroid side-effects.

Get access to the full text of this article

Ancillary